BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 29436692)

  • 1. Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.
    Janyst K; Janyst M; Siernicka M; Lasek W
    Oncol Rep; 2018 Apr; 39(4):1999-2005. PubMed ID: 29436692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
    Takai N; Ueda T; Nishida M; Nasu K; Narahara H
    Int J Mol Med; 2006 Feb; 17(2):323-9. PubMed ID: 16391833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
    Liu L; Sun X; Xie Y; Zhuang Y; Yao R; Xu K
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29945926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scriptaid effects on breast cancer cell lines.
    Giacinti L; Giacinti C; Gabellini C; Rizzuto E; Lopez M; Giordano A
    J Cell Physiol; 2012 Oct; 227(10):3426-33. PubMed ID: 22213035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of HDAC Inhibitor Scriptaid on IM9 Cell Line and Its Mechanism].
    Liu LL; Sun XY; Xie Y; Han DY; Yao RS; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1116-1121. PubMed ID: 30111417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
    Abaza MS; Bahman AM; Al-Attiyah RJ; Kollamparambil AM
    Tumour Biol; 2012 Dec; 33(6):1951-72. PubMed ID: 23011889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects.
    Janaki Ramaiah M; Naushad SM; Lavanya A; Srinivas C; Anjana Devi T; Sampathkumar S; Dharan DB; Bhadra MP
    Gene; 2017 Sep; 627():379-386. PubMed ID: 28668345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity.
    Sharma V; Koul N; Joseph C; Dixit D; Ghosh S; Sen E
    J Cell Mol Med; 2010 Aug; 14(8):2151-61. PubMed ID: 19583803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells.
    Lee EJ; Lee BB; Kim SJ; Park YD; Park J; Kim DH
    Int J Oncol; 2008 Oct; 33(4):767-76. PubMed ID: 18813790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
    Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
    PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
    Son DS; Wilson AJ; Parl AK; Khabele D
    Cancer Biol Ther; 2010 Jun; 9(11):928-35. PubMed ID: 20404564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scriptaid inhibits cell survival, cell cycle, and promotes apoptosis in multiple myeloma via epigenetic regulation of p21.
    Yao R; Han D; Sun X; Xie Y; Wu Q; Fu C; Yao Y; Li H; Li Z; Xu K
    Exp Hematol; 2018 Apr; 60():63-72. PubMed ID: 29305109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines.
    Ying H; Zhang Y; Lin S; Han Y; Zhu HZ
    Int J Mol Med; 2010 Aug; 26(2):265-72. PubMed ID: 20596607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus.
    Fox CR; Parks GD
    Viruses; 2019 May; 11(5):. PubMed ID: 31083335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.
    Pradhan S; Mahajan D; Kaur P; Pandey N; Sharma C; Srivastava T
    Oncotarget; 2016 Nov; 7(44):71841-71855. PubMed ID: 27708247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation.
    Kuribayashi T; Ohara M; Sora S; Kubota N
    Int J Mol Med; 2010 Jan; 25(1):25-9. PubMed ID: 19956898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
    Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
    Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.